0000000000198964

AUTHOR

Heinz Reichmann

showing 11 related works from this author

Practical importance of neuroprotection in Parkinson's disease.

2003

Consensus could be reached that there is overwhelming evidence of preclinical neuroprotection. However, the evidence of neuroprotection/neurorescue under clinical conditions is limited. Lessons from clinical trials designed to show neuroprotection (selegiline, amantadine, dopamine agonists) demonstrate that with the drugs available neuroprotection/neurorescue has to start as early as possible. A PET-controlled clinical trial with ropinirole shows that there seems to be a good chance for neuroprotection in the early phase of Parkinson's disease in patients treated from the very beginning of the disease while there is no such benefit in patients with a late start of a neuroprotective therapeu…

medicine.medical_specialtyNeurologyParkinson's diseaseIndolesBioinformaticsNeuroprotectionAntiparkinson AgentsDegenerative diseaseSelegilineAmantadineMedicineHumansbusiness.industrySelegilineAmantadineParkinson Diseasemedicine.diseaseClinical trialRopiniroleNeuroprotective AgentsNeurologyDopamine AgonistsNeurology (clinical)businessNeurosciencemedicine.drugJournal of neurology
researchProduct

Chronic progressive external ophthalmoplegia with a novel mitochondrial DNA deletion and a mutation in the tRNALEU(UUR) gene

1999

Large-scale deletions and point mutations of the mitochondrial DNA are generally accepted as being involved in the pathogenesis of diseases associated with mitochondrial encephalomyopathies such as Kearns-Sayre syndrome and chronic progressive external ophthalmoplegia (CPEO). We screened suspected patients using polymerase chain reaction techniques, Southern blot analyses, and muscle biopsy specimens. We report on a novel 4,953-base pair deletion associated with a familial occurrence of a tRNA Leu(UUR) T3250C point mutation in a young female patient clinically diagnosed with CPEO. This deletion is not flanked by direct repeats, so slip replication and homologous recombination do not seem li…

GeneticsMutationMitochondrial DNAPoint mutationRespiratory chainBiologyMitochondrionmedicine.diseasemedicine.disease_causeHeteroplasmyDrug DiscoverymedicineChronic progressive external ophthalmoplegiaMitochondrial EncephalomyopathiesDrug Development Research
researchProduct

Focal myositis of the temporal muscle

1993

Focal myositis is a rare inflammatory disease of the skeletal muscle that may involve any part of the body. We present a 19-year-old man with a short history of a painful pseudotumor in the right temporal region. MRI pictures showed a swollen right temporal muscle and muscle biopsy revealed the characteristic histological and immunocytochemical findings of polymyositis.

AdultMalePathologymedicine.medical_specialtyPhysiologyBiopsyTemporal musclePolymyositisNecrosisCellular and Molecular NeurosciencePhysiology (medical)BiopsymedicineHumansMyositisMuscle biopsyMyositismedicine.diagnostic_testbusiness.industryMusclesSkeletal muscleHistologyMagnetic resonance imagingAnatomymedicine.diseaseMagnetic Resonance Imagingmedicine.anatomical_structureNeurology (clinical)businessMuscle & Nerve
researchProduct

Glucocorticoid-sensitive hereditary inclusion body myositis.

1996

We report a hereditary muscle disorder with features of inclusion body myositis (IBM) in two adult sisters with slowly progressive asymmetrical muscle weakness. The findings of light microscopic and ultrastructural investigations of muscle biopsy specimens were consistent with a diagnosis of IBM. Both patients improved and stabilized on immunosuppressive treatment with corticosteroids and azathioprine. This differentiates our patients from other sporadic and familial cases of IBM. Clinical and histological features are described and compared with those of other previously reported families with IBM.

musculoskeletal diseasesPathologymedicine.medical_specialtyNeurologyeducationMuscle Fibers SkeletalAzathioprineMuscle disorderMyositis Inclusion Bodyparasitic diseasesmedicineHumansGlucocorticoidsMyositisImmunosuppression TherapyMuscle biopsymedicine.diagnostic_testbusiness.industryMuscle weaknessMiddle Agedmedicine.diseasePrognosisMicroscopy ElectronNeurologyFemaleNeurology (clinical)medicine.symptomInclusion body myositisbusinessGlucocorticoidmedicine.drugJournal of neurology
researchProduct

Familial mixed congenital myopathy with rigid spine phenotype

1997

We describe a father and daughter with a rigid spine syndrome and proximal myopathy. The index patient was a 42-year-old man, who died from respiratory failure after a lifelong, slowly progressive proximal myopathy and a rigid spine phenotype. This was morphologically characterized by cytoplasmic bodies, increased desmin, features of reducing-body myopathy, and sarcoplasmic and intranuclear tubulofilamentous inclusions. These cases are characterized by an early onset and possibly autosomal-dominant inheritance, with associated complex structural hallmarks of both desmin-related and inclusion body myopathies. Together they may be defined as a complex mixed congenital myopathy with a rigid sp…

Mixed congenital myopathyPathologymedicine.medical_specialtyPhysiologybusiness.industryRIGID SPINE SYNDROMEAnatomymusculoskeletal systemRigid spinePhenotypeTubulofilamentous inclusionsCellular and Molecular NeuroscienceRespiratory failurePhysiology (medical)medicineDesminNeurology (clinical)medicine.symptomMyopathybusinessMuscle & Nerve
researchProduct

Fabry Disease With Concomitant Lewy Body Disease

2019

AbstractAlthough Gaucher disease can be accompanied by Lewy pathology (LP) and extrapyramidal symptoms, it is unknown if LP exists in Fabry disease (FD), another progressive multisystem lysosomal storage disorder. We aimed to elucidate the distribution patterns of FD-related inclusions and LP in the brain of a 58-year-old cognitively unimpaired male FD patient suffering from predominant hypokinesia. Immunohistochemistry (CD77, α-synuclein, collagen IV) and neuropathological staging were performed on 100-µm sections. Tissue from the enteric or peripheral nervous system was unavailable. As controls, a second cognitively unimpaired 50-year-old male FD patient without LP or motor symptoms and 3…

complications [Lewy Body Disease]MalePathologyAutopsyDisease0302 clinical medicineHypokinesiapathology [Brain]Lysosomal storage diseasespathology [Neurons]metabolism [alpha-Synuclein]metabolism [Fabry Disease]pathology [Astrocytes]Neuronsα-Synuclein0303 health sciencesParkinsonismTrihexosylceramidesBrainGeneral MedicineMiddle AgedParkinson diseasecomplications [Fabry Disease]Neurologymetabolism [Neurons]alpha-Synucleinmedicine.symptomLewy Body Diseasemedicine.medical_specialtymetabolism [Lewy Body Disease]Context (language use)Substantia nigrametabolism [Trihexosylceramides]Pathology and Forensic Medicineblood supply [Brain]03 medical and health sciencesCellular and Molecular Neuroscienceα-Galactosidase AmedicineHumansddc:610030304 developmental biologypathology [Lewy Bodies]Fabry diseasebusiness.industryPars compactapathology [Lewy Body Disease]Lewy bodies/neuritesOriginal Articlesmetabolism [Lewy Bodies]medicine.diseaseFabry diseasemetabolism [Brain]AstrocytesLewy BodiesNeurology (clinical)CD77pathology [Fabry Disease]business030217 neurology & neurosurgeryJournal of Neuropathology and Experimental Neurology
researchProduct

A mild juvenile variant of type IV glycogenosis.

1992

The mild juvenile form of type IV glycogenosis, confirmed by a profound deficiency of the brancher enzyme in tissue specimens is reported from three Turkish male siblings who, foremost, suffered from chronic progressive myopathy. Muscle fibers contained polyglucosan inclusions of typical fine structure, i.e. a mixture of granular and filamentous glycogen. They reacted strongly for myophosphorylase, but were resistant to diastase. These inclusions were ubiquitinated and reacted with antibody KM-279 which previously has been shown to bind to Lafora bodies, corpora amylacea and polyglucosan material in hepatic and cardiac cells of type IV glycogenosis as well as polyglucosan body myopathy with…

Muscle tissueMalemedicine.medical_specialtyBiologychemistry.chemical_compoundGlycogen Storage Disease Type IVDevelopmental NeuroscienceInternal medicineSweat glandmedicineHumansGlycogen storage disease type IVMyopathyChildGlycogenStaining and LabelingHistocytochemistryMusclesInfantGeneral Medicinemedicine.diseaseEnzyme assaySweat Glandsmedicine.anatomical_structureEndocrinologychemistryMyophosphorylasePediatrics Perinatology and Child Healthbiology.proteinNeurology (clinical)medicine.symptomCorpora amylaceaBraindevelopment
researchProduct

A G468-T AMPD1 mutant allele contributes to the high incidence of myoadenylate deaminase deficiency in the Caucasian population.

2002

Myoadenylate deaminase deficiency is the most common metabolic disorder of skeletal muscle in the Caucasian population, affecting approximately 2% of all individuals. Although most deficient subjects are asymptomatic, some suffer from exercise-induced myalgia suggesting a causal relationship between a lack of enzyme activity and muscle function. In addition, carriers of this derangement in purine nucleotide catabolism may have an adaptive advantage related to clinical outcome in heart disease. The molecular basis of myoadenylate deaminase deficiency in Caucasians has been attributed to a single mutant allele characterized by double C to T transitions at nucleotides +34 and +143 in mRNA enco…

ThreonineDNA ComplementaryGenotypeBlotting WesternGlycineMetabolic myopathyBiologyCompound heterozygosityPolymerase Chain ReactionWhite PeopleAMP DeaminaseMetabolic DiseasesMuscular DiseasesGenotypemedicineHumansAlleleTransversionMuscle SkeletalGenetics (clinical)AllelesElectromyographyPoint mutationMetabolic disorderAMP deaminasemedicine.diseaseMolecular biologyPhenotypeNeurologyPediatrics Perinatology and Child HealthMutationNeurology (clinical)DNA ProbesNeuromuscular disorders : NMD
researchProduct

Mutation analysis in myophosphorylase deficiency (McArdle's disease).

1998

Inherited deficiency of myophosphorylase leads to glycogen storage disease type V (McArdle's disease). We performed mutation analysis in 9 patients of eight unrelated families from Germany with typical cliniclal presentation of myophos-phorylase deficiency. Beside previously described mutations we identified four novel mutations in the myophorsphorylase gene. Four patients were homozygous for a nonsense mutation Arg49Stop that has been reported to be the most common mutation in white patients. Two affected siblings were compound heterozygotes for a novel missense mutation Gly685Arg and the nonsense mutation Arg49Stop. One patient carried a novel nonsense mutation Arg575Stop and a previously…

AdultMaleAdolescentNonsense mutationDNA Mutational AnalysisBiologyCompound heterozygosityPolymerase Chain ReactionmedicineMissense mutationHumansAmino Acid SequenceChildCodonAgedGeneticsTransition (genetics)Base SequenceHomozygoteMiddle Agedmedicine.diseaseNeurologyMyophosphorylaseMutation (genetic algorithm)MutationMutation testingGlycogen Storage Disease Type VFemaleNeurology (clinical)Glycogen storage disease type VPolymorphism Restriction Fragment LengthAnnals of neurology
researchProduct

Changes of energy metabolism, myosin light chain composition, lactate dehydrogenase isozyme pattern and fibre type distribution of denervated fast-tw…

1985

The influence of low frequency (8-10 Hz) electrical stimulation on denervated fast-twitch muscle from rabbit was investigated. Prolonged direct stimulation of denervated muscle resulted in higher oxidative enzyme activities. Furthermore, single fibre analyses for succinate dehydrogenase showed a more uniform distribution of activity in stimulated-denervated muscle when compared to normal muscle. As was also the case following stimulation of innervated muscle, glycolytic enzymes were decreased in activity and the LDH-isozyme pattern was also shifted towards heart type. No change of the myosin light chain pattern could be observed after 56 days of stimulation.

Myosin light-chain kinaseChemical PhenomenaPhysiologyClinical BiochemistryStimulationMyosinschemistry.chemical_compoundPhysiology (medical)Lactate dehydrogenaseMyosinAnimalsDenervationMuscle DenervationLagomorphaL-Lactate DehydrogenasebiologyHistocytochemistryChemistryMusclesSuccinate dehydrogenasebiology.organism_classificationElectric StimulationMuscle DenervationIsoenzymesChemistrybiology.proteinBiophysicsRabbitsEnergy MetabolismPfl�gers Archiv European Journal of Physiology
researchProduct

Oculopharyngeal muscular dystrophy in a northern German family linked to chromosome 14q, and presenting carnitine deficiency

1997

We report the evaluation of oculopharyngeal muscular dystrophy (OPMD) in a large northern German family, which can be traced back six generations and is unrelated to French-Canadian families. The symptoms in this family start at about 50 years of age and include dysphagia, bilateral ptosis, and in some cases a slowly progressive atrophy and weakness of other extraocular, facial or limb girdle muscles. The muscle biopsies showed the pathognomonic ultrastructural finding of characteristic intranuclear filaments. Linkage analysis confirmed that this family is also linked to chromosome 14q markers. Haplotype analysis revealed that a unique haplotype segregates with the disease which is differen…

AdultMaleProbandPathologymedicine.medical_specialtyWeaknessGenetic LinkageBiopsyBiologyMuscular DystrophiesOculopharyngeal muscular dystrophySural NervePathognomonicGenetic linkageCarnitineGermanymedicineHumansCarnitineGenetics (clinical)AgedChromosomes Human Pair 14Family HealthGeneticsElectromyographyHaplotypeMiddle Agedmedicine.diseaseDysphagiaMitochondriaPedigreeMicroscopy ElectronPhenotypeNeurologyOculomotor MusclesPediatrics Perinatology and Child HealthPharyngeal MusclesFemaleNeurology (clinical)medicine.symptommedicine.drugNeuromuscular Disorders
researchProduct